Imamura et al. [150] determined that Src/c-Abl could be an efficient target for ALS treatment, based on HTS conducted for 1416 compounds, using ALS survival of motor neurons generated from an ALS patient harbouring SOD1 mutations. This evidence concerns the gene SRC and amyotrophic lateral sclerosis.